Dual ACE/NEP Inhibitor Pills Lower Blood Pressure Through Two Mechanisms Simultaneously
Orally active dual ACE/NEP inhibitors lowered blood pressure in hypertensive rats by simultaneously blocking angiotensin formation and protecting natriuretic peptides.
Quick Facts
What This Study Found
Orally active dual ACE/NEP inhibitors lowered blood pressure in hypertensive rats through combined angiotensin blockade and natriuretic peptide protection.
Key Numbers
How They Did This
Researchers used rational drug design to create dual inhibitors, tested their ability to block both enzymes in vitro, measured oral bioavailability, and assessed blood pressure effects in experimentally hypertensive rats.
Why This Research Matters
Combining two blood pressure-lowering mechanisms in one pill could provide better treatment than either alone. This approach eventually led to drugs like sacubitril/valsartan (Entresto) for heart failure.
The Bigger Picture
This rational drug design approach eventually led to sacubitril/valsartan (Entresto), now standard for heart failure. The concept of protecting beneficial peptides while blocking harmful ones revolutionized cardiovascular medicine.
What This Study Doesn't Tell Us
Animal study in rats. Oral bioavailability and efficacy in rats may not predict human pharmacology. Long-term safety not assessed.
Questions This Raises
- ?Could dual inhibitors replace separate ACE inhibitors and NEP inhibitors?
- ?What advantages does dual inhibition offer over either mechanism alone?
Trust & Context
- Key Stat:
- Dual mechanism, oral dosing Single molecules inhibiting both ACE and NEP achieved oral bioavailability and blood pressure lowering in hypertensive rats
- Evidence Grade:
- Moderate — animal study with rational drug design approach. Multiple compounds tested with structure-activity relationships.
- Study Age:
- Published in 1994 (32 years ago). Led to the development of sacubitril/valsartan, approved 2015 for heart failure.
- Original Title:
- New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
- Published In:
- Journal of medicinal chemistry, 37(8), 1070-83 (1994)
- Authors:
- Fournié-Zaluski, M C, Coric, P, Turcaud, S, Rousselet, N, Gonzalez, W, Barbe, B, Pham, I, Jullian, N, Michel, J B, Roques, B P
- Database ID:
- RPEP-00291
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why combine ACE and NEP inhibition?
ACE inhibitors block the production of angiotensin II (which raises blood pressure). NEP inhibitors protect natriuretic peptides (which lower blood pressure). Combining both provides complementary blood pressure lowering.
Did this lead to real drugs?
Yes — this concept led to sacubitril (an NEP inhibitor) combined with valsartan (an angiotensin blocker), marketed as Entresto, which is now a standard treatment for heart failure.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00291APA
Fournié-Zaluski, M C; Coric, P; Turcaud, S; Rousselet, N; Gonzalez, W; Barbe, B; Pham, I; Jullian, N; Michel, J B; Roques, B P. (1994). New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.. Journal of medicinal chemistry, 37(8), 1070-83.
MLA
Fournié-Zaluski, M C, et al. "New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.." Journal of medicinal chemistry, 1994.
RethinkPeptides
RethinkPeptides Research Database. "New dual inhibitors of neutral endopeptidase and angiotensin..." RPEP-00291. Retrieved from https://rethinkpeptides.com/research/fournie-zaluski-1994-new-dual-inhibitors-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.